{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:11:49Z","timestamp":1782180709976,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009878","name":"Regione del Veneto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijcard.2019.04.061","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T01:40:04Z","timestamp":1555638004000},"page":"72-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Real-world persistence with direct oral anticoagulants (DOACs) in na\u00efve patients with non-valvular atrial fibrillation"],"prefix":"10.1016","volume":"288","author":[{"given":"Eliana","family":"Ferroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Fedeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentian","family":"Denas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.04.061_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(00)01107-4","article-title":"Epidemiology and natural history of atrial fibrillation: clinical implications","volume":"37","author":"Chugh","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0020","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893\u2013962.","DOI":"10.5603\/KP.2016.0172"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0025","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart association Task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 2014;64:e1\u201376."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis\u2014task force on anticoagulants in heart disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.ijcard.2019.04.061_bb0035","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2008.03059.x","article-title":"Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?","volume":"6","author":"Gallagher","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.22204","article-title":"Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation","volume":"37","author":"Savelieva","year":"2014","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0045","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al., ARISTOTLE Committees and Investigators, Apixaban versus warfarin in patients with atrial fibrillation, N. Engl. J. Med. 365 (11) (Sep. 15 2011) 981\u201399;"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0050","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al., RE-LY Steering Committee and Investigators, Dabigatran versus warfarin in patients with atrial fibrillation, N. Engl. J. Med. 361 (12) (Sep. 17 2009) 1139\u20131151."},{"issue":"4","key":"10.1016\/j.ijcard.2019.04.061_bb0055","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","article-title":"Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry","volume":"17","author":"Beyer-Westendorf","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0060","doi-asserted-by":"crossref","unstructured":"Camm AJ, Amarenco P, Haas S, et al., XANTUS Investigators, XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation, Eur. Heart J. 37 (14) (Apr. 7 2016) 1145\u20131153;","DOI":"10.1093\/eurheartj\/ehv466"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0065","doi-asserted-by":"crossref","unstructured":"Coleman CI, Tangirala M, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in the United States, PLoS One 11 (6) (Jun. 21 2016), e015776.","DOI":"10.1371\/journal.pone.0157769"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2017.09.029","article-title":"Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in na\u00efve patients with non-valvular atrial fibrillation: propensity score matched cohort study","volume":"249","author":"Denas","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0075","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/CIRCOUTCOMES.113.000192","article-title":"Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin","volume":"6","author":"Zalesak","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011471","article-title":"Early real-worldevidence of persistence on oral anticoagulants for stroke pre-vention in non-valvular atrial fibrillation: a cohort study in UKprimary care","volume":"6","author":"Johnson","year":"2016","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.ijcard.2019.04.061_bb0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.acvd.2017.10.003","article-title":"Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: a cohort study in primary care in France","volume":"111","author":"Collings","year":"2018","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijcard.2017.01.098","article-title":"Permanent discontinuation of non- vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation","volume":"236","author":"Vedovati","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2019.04.061_bb0095","first-page":"113","article-title":"Non-persistence real world studies found a risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation","volume":"109","author":"Cataldo","year":"2018","journal-title":"Recenti Prog. Med."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","article-title":"Warfarin discontinuation after starting warfarin for atrial fibrillation","volume":"3","author":"Fang","year":"2010","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0105","first-page":"51","article-title":"Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism","volume":"4","author":"Kneeland","year":"2010","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0110","first-page":"699","article-title":"Ensuring medication adherence with direct oral anticoagulant drugs","volume":"133","author":"Di Minno","year":"2014","journal-title":"lessons from adherence with vitamin K antagonists (VKAs). Thromb. Res."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MLR.0b013e3181c132ad","article-title":"Patient, physician, and payment predictors of statin adherence","volume":"48","author":"Chan","year":"2010","journal-title":"Med. Care"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0125","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/eurjhf\/hfp142","article-title":"Adherence to medication according to sex and age in the CHARM programme","volume":"11","author":"Granger","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0130","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2036.2008.03698.x","article-title":"Review article: medication non-adherence in ulcerative colitis \u2013 strategies to improve adherence with mesalazine and other maintenance therapies","volume":"27","author":"Hawthorne","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","article-title":"Variations in patients' adherence to medical recommendations: a quantitative review of 50\u202fyears of research","volume":"42","author":"DiMatteo","year":"2004","journal-title":"Med. Care"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0140","first-page":"30","article-title":"Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events","volume":"62","author":"Demyttenaere","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0145","doi-asserted-by":"crossref","unstructured":"O'Brien EC, Simon DN, Allen LA, et al. Reasons for warfarin discontinuation in the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Am. Heart J. 2014;168:487\u201494.","DOI":"10.1016\/j.ahj.2014.07.002"},{"key":"10.1016\/j.ijcard.2019.04.061_bb0150","series-title":"Adherence to Long-term Therapies: Evidence for Action","author":"Sabate\u00b4","year":"2003"},{"issue":"4","key":"10.1016\/j.ijcard.2019.04.061_bb0155","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"10.1016\/j.ijcard.2019.04.061_bb0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"July","key":"10.1016\/j.ijcard.2019.04.061_bb0165","first-page":"1","article-title":"Determinants of patient adherence: a review of systematic reviews","volume":"4","author":"Kardas","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.04.061_bb0170","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/STROKEAHA.110.611905","article-title":"Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence","volume":"42","author":"Broderick","year":"2011","journal-title":"Stroke."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319305765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319305765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:42:07Z","timestamp":1759092127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527319305765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":34,"alternative-id":["S0167527319305765"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.04.061","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world persistence with direct oral anticoagulants (DOACs) in na\u00efve patients with non-valvular atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.04.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}